No Increase in Blood Pressure Assessed With the 24-h Holter Monitoring in Patients With Episodic Migraine During Early Treatment With Anti-CGRP Monoclonal Antibodies: A Prospective Observational Study (SAFHYPER)
Abstract
BACKGROUND: Migraine is associated with an increased cardiovascular risk, including hypertension. Anti-calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs) are effective preventive treatments, but concerns have been raised about their potential hypertensive effects. Herein, we assess the early changes in blood pressure (BP) during anti-CGRP mAbs treatment in patients with migraine using 24-h Holter monitoring.
METHODS: We conducted a prospective, real-world study including 20 patients with episodic migraine (EM) during the early treatment with anti-CGRP mAbs. Participants underwent 24-h Holter BP monitoring before treatment and 4 weeks after the first injection. The primary outcome was the change in mean systolic BP (SBP). Secondary outcomes included changes in diastolic BP (DBP), differential BP, diurnal/nocturnal values, heart rate (HR), and dipping patterns.
RESULTS: Mean 24-h SBP and DBP showed non-significant differences after treatment (-2.4 mmHg and -1.8 mmHg, p = 0.075). No significant changes were observed in diurnal BP, but a significant reduction in nocturnal DBP was detected (-2.6 mmHg, p = 0.026). Consistently, the proportion of patients with a physiological dipping profile increased from 45.0% to 85.0% post-treatment (p = 0.008). HR remained unchanged, and no patients had mean PAD ≥ 130/80. No adverse events were reported.
CONCLUSION: Anti-CGRP mAbs did not induce clinically relevant BP increases in the early treatment phase and were associated…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 20 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.